High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. Here's why these two high-yield ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer's marketing ...

Biotech-stock investing has one tough test for success - and it's about to get easier ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood disorder sickle cell. Instead of using clinical benefit as the benchmark, the FDA approved Oxbryta based on ...

UBS analyst Trung Huynh maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $31.00. The company’s shares closed yesterday at $26.72. Huynh covers the ...

Shares of Moderna and BioNTech fell 5% and 6% respectively. Pfizer's stock and the stocks of the British vaccine creator GSK both only fell 2%, according to NBC News. The drops come despite Kennedy's ...

Though most have underperformed in 2024, these 9 S&P 500 stocks offer a 5% dividend yield or better.